First Citizens Bank & Trust Co. Purchases 1,920 Shares of Intuitive Surgical, Inc. $ISRG

First Citizens Bank & Trust Co. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 22,884 shares of the medical equipment provider’s stock after purchasing an additional 1,920 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Intuitive Surgical were worth $9,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of ISRG. Bank of New York Mellon Corp bought a new position in Intuitive Surgical during the 2nd quarter valued at $1,335,753,000. J. Stern & Co. LLP increased its stake in Intuitive Surgical by 18,504.6% in the 4th quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after buying an additional 1,027,475 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Intuitive Surgical by 17.4% in the fourth quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after buying an additional 611,268 shares during the period. Finally, Capitolis Liquid Global Markets LLC boosted its position in shares of Intuitive Surgical by 1,070.2% in the fourth quarter. Capitolis Liquid Global Markets LLC now owns 503,171 shares of the medical equipment provider’s stock worth $284,976,000 after buying an additional 460,171 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, Director Amy L. Ladd sold 400 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the sale, the director owned 251 shares in the company, valued at $95,129. This represents a 61.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $374.44, for a total value of $407,765.16. Following the sale, the vice president owned 1,026 shares of the company’s stock, valued at approximately $384,175.44. The trade was a 51.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock valued at $4,891,989 in the last ninety days. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BTIG Research decreased their target price on shares of Intuitive Surgical from $469.00 to $454.00 and set a “buy” rating for the company in a research note on Monday. Wall Street Zen downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. Sanford C. Bernstein restated an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Citigroup cut their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a report on Friday, July 17th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $498.83.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Erste Group Bank raised its FY2026 EPS forecast for Intuitive Surgical to $8.94 from $8.93, above the consensus estimate of $8.87. The firm also increased its FY2027 forecast to $10.09 from $10.06, indicating modestly improving expectations for long-term profitability. MarketBeat Intuitive Surgical analyst estimates
• Positive Sentiment: Zacks upgraded ISRG to a Rank #2, or “Buy,” citing improving earnings prospects. UBS also reiterated its Buy rating and maintained a $500 price target, pointing to the company’s long-term robotic-surgery growth runway. Zacks upgrade article UBS Buy rating article
• Positive Sentiment: Intuitive Surgical’s submission of a next-generation robotic endoscope to the FDA could expand the company beyond surgical procedures into gastrointestinal care. Approval would create an additional growth opportunity, although the timing and outcome remain uncertain. ISRG GI opportunity article
• Neutral Sentiment: Investor attention remains elevated ahead of the company’s expected quarterly earnings release. Recent coverage highlights ISRG’s strong sales growth, cash generation and debt-free balance sheet, but also notes that the shares trade at a substantially higher valuation than some healthcare peers.
• Negative Sentiment: BTIG lowered its price target to $454 from $469 while retaining a Buy rating. The reduction suggests more limited near-term upside despite continued confidence in the business. BTIG price target article
• Negative Sentiment: One valuation analysis argues that ISRG could be about 31% overvalued following its earnings-outlook upgrade. With a price-to-earnings ratio near 48 based on the supplied market data, strong execution may already be reflected in the stock price.

Intuitive Surgical Price Performance

Shares of ISRG opened at $422.06 on Wednesday. The company has a market capitalization of $149.11 billion, a PE ratio of 48.35, a price-to-earnings-growth ratio of 3.23 and a beta of 1.46. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The company’s fifty day moving average price is $388.49 and its 200 day moving average price is $410.14.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. During the same period in the prior year, the company earned $1.81 earnings per share. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. Analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.